When each was combined with Clb in first-line CLL

GAZYVA demonstrated higher response rates vs rituximab product 1

More patients achieved a complete responsea with GAZYVA (obinutuzumab) + Clb 1

GAZYVA CLL-11 Complete Response Chart
  • Overall response rates with GAZYVA + Clb were greater than those with rituximab product + Clb (79.6% vs 66.3%)
  • GAZYVA + Clb delivered longer median duration of response vs rituximab product + Clb (19.6 months vs 9.7 months)

Additional clinical data

In patients who achieved a complete response,a the rate of minimal residual disease (MRD) negativityb in the bone marrow was higher in the GAZYVA + Clb arm 1

GAZYVA CLL-11 MRD Negativity in Bone Marrow Chart
  • In patients who achieved a complete response,a 41% (39 of 94 patients) of the GAZYVA treated arm and 12% (4 of 34 patients) of the rituximab product treated arm were MRD negative in peripheral blood

bMRD was evaluated using allele-specific oligonucleotide polymerase chain reaction. The cutoff for a negative status was one CLL cell per 104 leukocytes in the sample (ie, an MRD value of <10-4 was considered negative). Bone marrow samples were collected at the end of treatment, and peripheral blood samples were collected at least 3 months after the end of treatment. 1,7